By Funded Work Editorial Desk · AI-assisted summary · sources linked below when available
Xylyx Bio pairs FDA orphan designation with a $3M NIH grant for its bioengineered lung
The Direct-to-Phase II SBIR award from the National Institutes of Health supplies $3M in non-dilutive funding over two years for safety and feasibility work, including planned first-in-human transplant studies.
Xylyx Bio picked up two milestones at once: the U.S. Food and Drug Administration granted Orphan Drug Designation to its Inspirex Lung product, and the National Institutes of Health committed a $3M Direct-to-Phase II Small Business Innovation Research grant to push the investigational bioengineered lung graft toward the clinic.
The NIH money is non-dilutive and runs over two years, funding safety and feasibility studies — including planned first-in-human transplantation studies. That makes the grant a rare thing in early-stage medtech: runway that does not come with a cap table consequence.
Inspirex Lung is aimed at patients with lung failure who require transplantation. The product relies on Xylyx Bio's proprietary XC Platform and xenogeneic cross-circulation to deliver systemic physiologic support to injured donor lungs, with the aim of restoring organs that otherwise would fail transplant criteria. The company says the cross-circulation approach has been evaluated in preclinical research published in journals including Nature Medicine and The Journal of Heart and Lung Transplantation.
The market logic the company is leaning on is stark: more than 75% of donated lungs currently go unused, frequently because of acute and potentially reversible injury. Xylyx argues that actively repairing donated lungs, rather than merely preserving or briefly assessing them, could widen the supply of organs available for transplantation.
The FDA's Orphan Drug Designation can unlock certain development incentives for therapies targeting rare diseases, but it is not an approval. Inspirex Lung remains investigational and has not been cleared by the FDA or any other regulatory authority, and its safety and effectiveness still have to be established through further clinical development.
"Patients with lung failure often die waiting for a transplant, while most donated lungs are not used," said Andrea Nye, MPH, MBA, president and chief executive officer of Xylyx Bio, calling the designation and the NIH award "important milestones" as the company advances toward first-in-human studies. Chief Scientific Officer John O'Neill, Ph.D., framed the work as a step beyond organ preservation and short-term assessment toward "active, sustained organ repair."
Patients with lung failure often die waiting for a transplant, while most donated lungs are not used. Inspirex Lung is designed to address both sides of that equation by restoring injured donor lungs that would otherwise go unused to increase the number of lungs available for transplantation. Orphan Drug Designation and this NIH SBIR award represent important milestones as Xylyx advances Inspirex Lung toward first-in-human clinical studies. — Andrea Nye, MPH, MBA, President and Chief Executive Officer of Xylyx Bio
About the Company
Received U.S. Food and Drug Administration Orphan Drug Designation for Inspirex Lung and a $2.99 million National Institutes of Health grant to advance development of the investigational bioengineered lung graft.
XYLYX BIO develops bioengineered human organ grafts to increase transplantable organ supply. Advance life-saving transplantation with the Inspirex™ platform.